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ABSTRACT 32 
This study compares the physiological responses of systemic-to-33 
pulmonary shunted single ventricle patients to pulsatile and continuous flow 34 
ventricular assist devices (VADs).  Performance differences between pulsatile 35 
and continuous flow VADs have been clinically observed, but the underlying 36 
mechanism remains poorly understood.  Six systemic-to-pulmonary shunted 37 
single ventricle patients (mean BSA=0.30 m2) were computationally simulated 38 
using a lumped-parameter network tuned to match patient specific clinical data.  39 
A first set of simulations compared current clinical implementation of VADs in 40 
single ventricle patients.  A second set modified pulsatile flow VAD settings with 41 
the goal to optimize cardiac output (CO).  For all patients, the best-case 42 
continuous flow VAD CO was at least 0.99 L/min greater than the optimized 43 
pulsatile flow VAD CO (p=0.001).  The 25 and 50 mL pulsatile flow VADs 44 
exhibited incomplete filling at higher heart rates that reduced CO as much as 45 
9.7% and 37.3% below expectations respectively.  Optimization of pulsatile flow 46 
VAD settings did not achieve statistically significant (p<0.05) improvement to CO.  47 
Results corroborate clinical experience that continuous flow VADs produce 48 
higher CO and superior ventricular unloading in single ventricle patients.  49 
Impaired filling leads to performance degradation of pulsatile flow VADs in the 50 
single ventricle circulation. 51 
52 
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1. Introduction 53 
Children born with single ventricle congenital heart defects require staged 54 
surgical intervention to enable survival.  The first of three stages involves 55 
insertion of a systemic-to-pulmonary shunt that provides the infant’s only source 56 
of pulmonary blood flow.  However, patients remain at risk of heart failure (HF) 57 
due to increased volume loading on the single working ventricle (Gewillig, 2005).  58 
A ventricular assist device (VAD) can be used as mechanical bridge support for 59 
these patients.  VADs have been used in single ventricle circulations (Calvaruso 60 
et al., 2007; Cardarelli et al., 2009; Chu et al., 2007) and normal circulations 61 
(Adachi and Fraser, 2011; Hetzer et al., 2006b; Stiller et al., 2003), but survival 62 
rates for pediatric patients with congenital heart defects remain approximately 63 
25% lower than those without (Morales et al., 2010) and outcomes worsen 64 
further in single ventricle cases.  Therefore, increased knowledge of mechanisms 65 
affecting VAD performance in single ventricle circulations is needed to improve 66 
clinical outcomes for these patients. 67 
VADs can be categorized as either pulsatile or continuous flow.  Pulsatile 68 
flow VADs emulate the heart’s distinct phases of diastole and systole.  The Berlin 69 
Heart EXCOR VAD remains the only such FDA approved device for infants.  70 
VAD blood flow is driven via membrane, and valves are located at the inlet and 71 
outlet of this “ventricle.”  Membrane motion is controlled by an air chamber 72 
connected to an external air compressor.  By contrast, continuous flow VADs use 73 
rotors to produce a pressure rise for a particular flow and rotational speed 74 
(Moazami et al., 2013).  Continuous flow designs generally have better reliability 75 
and smaller size while reducing risk of infection, bleeding, trauma, and thrombus 76 
(Cheng et al., 2014; Drews et al., 2008; Feller et al., 2007; Kato et al., 2011).  77 
While continuous flow devices are now used extensively in adults and older 78 
children, none are specifically designed for long-term use in infants.  Successful 79 
bridge treatment of pediatric patients with continuous flow VADs has been 80 
demonstrated (Miera et al., 2011), however further experience is needed in 81 
single ventricle circulations.  Studies have suggested pulsatile flow VADs may 82 
promote better ventricular unloading and more natural physiology (Cheng et al., 83 
2014; Drews et al., 2008; Klotz et al., 2004), however continuous flow VADs may 84 
encourage faster recovery of myocardial tissue due to less pulsatile trauma on 85 
the heart tissue (Frazier et al., 2004; Frazier and Myers, 1999). 86 
Computational simulations of the cardiovascular system can model the 87 
interaction of VADs and other devices with circulatory physiology and predict 88 
hemodynamics.  Lumped-parameter networks (LPN) and state space models 89 
offer a reduced-order modeling approach by making an analogy to electrical 90 
circuits and forming a system of ordinary differential equations (ODEs) solved by 91 
numerical integration (Ferreira et al., 2005; Kung et al., 2014).  In this study, we 92 
will use an LPN model to assess VAD performance for our patient cohort.  Three 93 
dimensional computational fluid dynamics (CFD) methods can obtain greater 94 
hemodynamic detail (Migliavacca et al., 2006; Peng et al., 2012), but coupling of 95 
VAD CFD simulations to physiologic models has only recently been 96 
accomplished (Neidlin et al., 2016).  This study improves over the previous work 97 
by incorporating a model describing ventricular suction induced by a VAD. 98 
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This study aims to understand physiological responses of stage 1 single 99 
ventricle patients to pulsatile and continuous flow VADs and to identify 100 
mechanistic explanations for differences in performance.  This will be evaluated 101 
on cohort and patient specific levels.  Recommendations for achieving optimal 102 
VAD performance in single ventricle patients will be provided within operational 103 
limitations of the VADs. 104 
 105 
2. Methods 106 
2.1. Overview of Study 107 
The LPN used in this study (Fig. 1) was based on our previous work (Kung 108 
et al., 2014).  To simulate VAD support, the inflow and outflow cannulas were 109 
connected to the ventricle and aorta respectively.  In clinical practice, the outflow 110 
cannula could be attached to one of several locations near the aorta, such as the 111 
neoaorta or innominate artery.  In the LPN, which is a simplified representation of 112 
vasculature, these locations each correspond to the aortic node.  A connection 113 
between the aorta and pulmonary arteries represented the systemic-to-114 
pulmonary shunt.  Respiration effects were assumed negligible. 115 
Clinical measurements from six stage 1 single ventricle patients (cohort 116 
body surface area (BSA) range 0.26-0.34 m2; mean 0.30 m2) were obtained from 117 
the Great Ormond Street Hospital, Medical University of South Carolina, and 118 
University of Michigan.  For the LPN simulations to accurately replicate each 119 
patient’s unique physiology, the LPN element values were tuned using a process 120 
similar to our previous works (Corsini et al., 2015, 2014; Kung et al., 2013) to 121 
match individual patient’s clinical measurements.  Once tuning was complete, 122 
ventricular contractility was set to zero to simulate HF. 123 
 124 
2.2. Simulation Setup and Protocol 125 
We have previously reported a clinical case of extracorporeal 126 
implementation of the Revolution VAD (Sorin Group, Italy) in a stage 1 single 127 
ventricle patient via 9 mm inner diameter (ID) Berlin Heart cannulas (Lal et al., 128 
2014).  However, insufficient data existed to construct a computational model for 129 
the Revolution VAD.  Therefore, we constructed a HeartWare VAD (HeartWare 130 
Inc., Framingham, Massachusetts) model for this study to resemble the 131 
continuous flow VAD scenarios similar to our previous clinical experience.  Due 132 
to the similar continuous flow centrifugal designs of the HeartWare and 133 
Revolution VADs, they would produce the same hemodynamics when generating 134 
the same pressure head.  The only variable setting for the continuous flow VAD 135 
was revolutions per minute (RPM). 136 
We modeled the Berlin Heart EXCOR VAD (Berlin Heart GmbH, Berlin, 137 
Germany) for the pulsatile flow scenarios in this study.  Variable VAD settings for 138 
the Berlin Heart were the device size, “heart rate” (HR), peak filling (PDIA) and 139 
ejection (PSYS) pressures, and diastolic filling ratio (DFR), which is the time ratio 140 
of diastole to the total VAD period.   141 
Two primary sets of simulations were done.  The first emulated current 142 
clinical implementation of VADs specific to stage 1 single ventricle patients.  The 143 
pulsatile flow VAD was simulated with the following ranges of settings: HR (15-144 
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105 BPM for 10 and 25 mL, 15-75 BPM for 50 mL), PDIA (-40 mmHg), PSYS (mean 145 
aortic pressure+100 mmHg), and DFR (60%).  The continuous flow VAD was 146 
simulated with rotor speeds from 1800-3400 RPM.  Cannula dimensions (Table 147 
1) specified by the manufacturers were used.  The second set of simulations 148 
investigated changes to pulsatile flow peak pressure and DFR settings to 149 
optimize cardiac output. 150 
The system of ODEs describing the LPN were solved with a fourth order 151 
Runge-Kutta time-integration method using FORTRAN (IBM Corp., Armonk, New 152 
York), and data were analyzed using MATLAB (MathWorks Inc., Natick, 153 
Massachusetts).  After simulations reached periodicity, data from the last cardiac 154 
period were used in the analyses. 155 
 156 
2.3. Statistics 157 
To determine statistical significance, hypothesis testing with p-values was 158 
done assuming a normal distribution.  For this study, the null hypothesis was that 159 
there is no difference in results between two samples.  The threshold for 160 
statistical significance was 0.05.  The t-statistic was used, and the probability for 161 
a two-tailed distribution was calculated. 162 
 163 
2.4. Ventricular Assist Device Modeling 164 
2.4.1. Pulsatile Flow VAD 165 
The Berlin Heart comes in several sizes ranging from 10 to 80 mL.  The 166 
10 and 25 mL sizes are common for pediatric use (Hetzer et al., 2006a; Stiller et 167 
al., 2003), and the 50 mL size is also occasionally used to achieve higher CO.  168 
Since the Berlin Heart is controlled by the external air compressor, the model 169 
prescribed VAD pressure, PCOMP, as a sinusoidal function (Fig. A1) 170 
𝑃஼ைெ௉ ൌ ቐ
𝑃ௌ௒ௌ ቀsin ቀ ௧∗గሺଵି஽ிோሻ∗௧ೇಲವቁቁ଴.ଵ                𝑠𝑦𝑠𝑡𝑜𝑙𝑒
𝑃஽ூ஺ sin ቀሺ௧ିሺଵି஽ிோሻ∗௧ೇಲವሻ∗గ஽ிோ∗௧ೇಲವ ቁ             𝑑𝑖𝑎𝑠𝑡𝑜𝑙𝑒                                      (1) 171 
where tVAD is the time of one VAD period and DFR is the diastolic filling ratio (a 172 
number between zero and one).  The air compressor is limited to HRs up to 173 
approximately 110, 100, and 60 BPM for the 10, 25, and 50 mL sizes 174 
respectively. 175 
 176 
2.4.2. Continuous Flow VAD 177 
For continuous flow VADs, little pulsatility exists once equilibrium occurs 178 
between the VAD and the patient’s physiology.  We used experimental data from 179 
literature for the HeartWare VAD to create trendlines (Fig. A2) in the form 180 
∆𝑃௏஺஽ ൌ 𝐴𝑄௏஺஽ଶ ൅ 𝐵𝑄௏஺஽ ൅ 𝐶                   (2) 181 
where PVAD is the pressure rise across the VAD, QVAD is the flowrate through 182 
the VAD, and A, B, and C are constants dependent on the VAD RPM (Moazami 183 
et al., 2013). 184 
 185 
2.5. Ventricular Suction Caused by VAD Operation 186 
We define resistance due to ventricular collapse induced by a VAD as the 187 
ventricular suction resistance, RSUC (mmHg.s/mL).  If the VAD attempts to draw 188 
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blood from the ventricle below its reference volume, which results in a negative 189 
ventricular pressure, the ventricle begins to collapse.  When this occurs, tissue 190 
may be drawn into the cannula or the septum may be drawn closer to the 191 
cannula (Salamonsen et al., 2015), both of which can inhibit blood flow.  Several 192 
models have been proposed in literature (Choi, 1998; Lim et al., 2010; Schima et 193 
al., 1990; Yu and Porter, 2006) to describe ventricular suction resistance induced 194 
by VADs in various animal experiments. 195 
The ventricular suction models from these previous studies did not 196 
produce suction responses during continuous flow VAD simulations consistent 197 
with our clinical observations.  Therefore, we developed a new model containing 198 
two components that improve its realism (Appendix B).  We first developed an 199 
allometric scaling law relating RSUC to BSA to generalize the model. Second, we 200 
combined experimental data from several prior works to create a ventricular 201 
suction model (R2=0.72) suitable for our cohort 202 
𝑅ௌ௎஼ ൌ ൜0                                                                           𝑃ௌ௏ ൐ 𝑃்ு0.2623ሺ0.9787௉಴ಲಿ െ 1ሻ𝐵𝑆𝐴ି଴.ଷସଽଶ          𝑃ௌ௏ ൑ 𝑃்ு                         (3) 203 
where PCAN is the inflow cannula pressure, PSV is the ventricular pressure, and 204 
PTH is the threshold pressure set to 0 mmHg. If complete flow obstruction (when 205 
the inflow cannula attaches to the collapsed ventricular wall) occurs, the value of 206 
PTH is set to the positive ventricular pressure needed to overcome the negative 207 
cannula pressure and “pop off” the cannula from the wall.  In this scenario PTH is 208 
calculated as 209 
𝑃்ு ൌ ห௉಴ಲಿሺ஽಴ಲಿሻ
మห
଼଴ଷଵ஻ௌ஺                (4) 210 
where DCAN is the inflow cannula ID in mm.  After complete flow obstruction ends, 211 
PTH is reset to 0 mmHg.  The complete developments of equations 3 and 4 are 212 
described in Appendix B. 213 
 214 
2.6. Passive Ventricular Pressure-Volume Relationship During Suction 215 
To properly utilize equation 3, we require a passive ventricular pressure-216 
volume relationship to replicate a physiologically appropriate trend at negative 217 
pressures.  This has been investigated by several studies (Burkhoff et al., 2005; 218 
Gilbert and Glantz, 1989; Nikolić et al., 1988).  We adopted the results of Nikolić 219 
et al. since they presented sufficient supporting data to reconstruct a usable 220 
model 221 
𝑃ௌ௏ ൌ 𝑆௡ ln ቀ௏ೄೇ௏బ ቁ               (5) 222 
where Sn is a stiffness property, VSV is the ventricular volume, and V0 is the 223 
reference volume for which pressure is zero.  Sn was independent of body mass, 224 
therefore the mean value from the study was used. 225 
 226 
3. Results 227 
3.1. LPN Tuning 228 
All pre-HF simulation results (Table C2) matched clinical measurements 229 
within 10% except for atrial pressure (up to 30.6%) in three patients, 230 
pulmonary flow (up to 19.8%) in two patients, and pulmonary pressure (11.6%) 231 
in one patient.  However, clinical measurements of pulmonary flow were subject 232 
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to fluctuations from turbulence in some patients, therefore we felt confident that 233 
convergence of other parameters to clinical measurements was sufficient to 234 
demonstrate the LPN represented patient physiologies well. 235 
 236 
3.2. Simulation of VAD Implementation in Clinical Practice 237 
3.2.1. Pulsatile Flow VAD 238 
 For a pulsatile flow VAD, the expected cardiac output (CO) is the VAD 239 
volume times VAD HR when flow through the aortic valve is zero.  At very low 240 
HRs for the 10 and 25 mL sizes, additional flow through the aortic valve 241 
produced by atrial contraction resulted in CO greater than the expected CO; 242 
these scenarios would not be observed in reality since such low HR settings 243 
would not be used clinically.  Expected CO was achieved for the 10 mL Berlin 244 
Heart at all HRs (Fig. 2).  However, reductions from expected CO occurred at 245 
higher HRs for the 25 and 50 mL sizes (Figs. 2 and 3a). 246 
Decreases in CO from expected with the 25 and 50 mL sizes were 247 
examined more closely by investigating the VAD’s filling and ejection 248 
performance.  For a pulsatile flow VAD to attain the expected CO, it must both fill 249 
and eject blood completely in each cardiac period.  Stroke volumes (SV) of the 250 
25 and 50 mL size VAD both showed decreases from expected at higher HRs 251 
(Fig. 4).  VMIN was 0 mL for all VAD sizes at all HRs, which implied that 252 
incomplete ejection never occurred.  Therefore, the drops in SV were solely due 253 
to incomplete filling.  We investigated several approaches to modifying VAD 254 
settings in order to reduce incomplete filling and optimize CO, however, no 255 
statistically significant improvement in CO was achieved (Appendix E). 256 
 257 
3.2.2. Continuous Flow VAD 258 
For the continuous flow VAD, RPM was the only variable setting.  CO of 259 
the HeartWare VAD increased steadily with RPM until reaching a maximum of 260 
3.10 L/min at 3000 RPM (Fig. 3b).  Beyond 3000 RPM, temporary periods of 261 
complete flow obstruction occurred and resulted in alternating periods of flow and 262 
no flow.  This increased RSUC and decreased CO.  Ventricular and atrial 263 
pressures both decreased steadily as unloading improved until reaching 264 
minimums of -2.83 and -0.47 mmHg at 3000 RPM.  The reduction in PSA 265 
occurred due to propagation of volume unloading upstream from the ventricle 266 
and demonstrated the VAD’s ability to alleviate congestion.  We also note the 267 
phasic suction response (Fig. 5) occurring in simulations of three patients at high 268 
RPMs with the continuous flow VAD.  In those patients, PCAN approached 269 
negative pressures low enough (e.g. -200 mmHg) to result in complete flow 270 
obstruction where the ventricular wall was sucked onto the opening of the inflow 271 
cannula. 272 
 273 
3.3. Patient Specific Results 274 
 Patient specific results were investigated to identify patient specific factors 275 
affecting outcomes and the differences between pulsatile and continuous flow 276 
VAD support at an individual level (Table 2).  Detailed physiological results of 277 
these simulations are in Table D2. 278 
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Due to volume loading from the pulmonary shunt, significant CO is desired 279 
in order to produce favorable clinical outcomes.  The target CO for these 280 
pediatric patients is BSA*CItarget, where CItarget is 6 L/min/m2.  The target CO was 281 
attained for all patients with both pulsatile and continuous flow.  For all six 282 
patients, the continuous flow VAD CO was at least 0.99 L/min greater than the 283 
optimized pulsatile flow VAD CO. Optimizing the settings of the pulsatile flow 284 
VAD increased CO for four patients, but the largest individual increase was only 285 
0.07 L/min (3.0%).  Therefore, the current clinical protocol for pulsatile flow VAD 286 
settings is close to optimum as-is. 287 
Pre-HF CO was the best predictor of VAD supported CO for both VAD 288 
types.  This was true for each patient in the cohort except for patient E.  Patient E 289 
had an atrial reference volume of 14.1 mL compared to a mean of 1.4 mL for the 290 
other five patients.  This reduced the VAD CO for patient E because patient E 291 
required a larger atrial volume than those of other patients to maintain the same 292 
atrial pressure needed to drive ventricular filling.   293 
For pulsatile flow, the 25 mL size produced greater CO than the 50 mL 294 
size in three patients.  Two of these patients (A and C) possessed the lowest pre-295 
HF CO and the other was patient E, who possessed the larger atrial reference 296 
volume.  Since the 25 mL size requires half as much filling per VAD period 297 
compared to the 50 mL size, the likelihood of incomplete filling is reduced.  This 298 
suggests using a smaller size pulsatile flow VAD for patients with low pre-HF CO. 299 
 Phasic complete flow obstruction occurred in simulations of three patients 300 
with the HeartWare VAD.  These patients had three of the four lowest pre-HF 301 
CO.  This indicates that optimal outcomes for patients with low pre-HF CO will 302 
occur at lower VAD RPM settings. 303 
 304 
4. Discussion 305 
It is dominantly observed in anecdotal clinical experiences of VAD support 306 
in single ventricle patients that continuous flow results in superior outcomes.  307 
However, these clinical experiences are rare and have not been well 308 
documented or published.  This computational study provides crucial data as an 309 
important first step to understand the physiological impacts of continuous versus 310 
pulsatile flow VAD support to the single ventricle circulation and to illustrate the 311 
potential underlying mechanisms leading to these impacts.  Since stage 1 312 
patients have parallel systemic and pulmonary circulations, greater CO is 313 
needed.  Therefore, these results should not be generalized to Fontan or double 314 
ventricle patients. 315 
Following clinical protocol, the maximum cohort mean CO were 2.23 and 316 
3.10 L/min with the Berlin Heart and HeartWare VAD respectively.  The mean 317 
atrial and ventricular pressures decreased to PSA=1.90 mmHg and PSV=0.29 318 
mmHg (Berlin Heart) and PSA=-0.47 mmHg and PSV=-2.83 mmHg (HeartWare 319 
VAD) from unsupported heart failure pressures (Table D1).  These results 320 
demonstrated that, while congestion was alleviated with both pulsatile and 321 
continuous flow VAD support, the continuous flow VAD produced superior 322 
maximum CO (p=0.001).  These findings corroborate current clinical experience 323 
of VAD implementation in single ventricle patients. 324 
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Reduction of SV at higher HRs for the pulsatile flow VAD occurred due to 325 
incomplete filling.  For the 50 mL size from 45 to 75 BPM, VMAX decreased from 326 
47.5 to 33.2 mL despite fairly constant RSUC.  This implied incomplete filling 327 
resulted from a combination of ventricular suction and reduced VAD diastolic 328 
time as HR increased. 329 
The concept of duty cycle can explain why continuous flow produced 330 
superior CO.  The continuous flow VAD effectively has a 100% duty cycle since 331 
filling and ejection are synonymous.  The pulsatile flow VAD has a reduced duty 332 
cycle since it can only fill or eject at any given time.  Other challenges to attaining 333 
expected CO for pulsatile flow in clinical practice can also be identified.  For the 334 
25 and 50 mL Berlin Heart, incomplete filling presented at higher HRs because 335 
time for filling was reduced.  Producing a high CO with a pulsatile flow VAD 336 
necessitates using a high HR, which then results in incomplete filling.  Despite 337 
optimizing VAD peak pressure and DFR settings, the VAD’s increased demand 338 
for blood during filling only tended to increase suction resistance rather than CO.  339 
Incomplete ejection is another potential limiting factor to CO.  However, since 340 
ejection occurs separately from filling, PSYS can be increased to eliminate 341 
incomplete ejection with no adverse effect on filling performance.  This was 342 
successfully demonstrated during the simulations of modified pulsatile flow VAD 343 
settings when PSYS was increased by 100 mmHg from clinical recommendation to 344 
prevent incomplete ejection (case 5, Table E1).  Therefore, incomplete ejection 345 
should generally not be a limiting factor of CO for a pulsatile flow VAD. 346 
In several patients, simulating the continuous flow VAD at high RPMs 347 
produced a phasic flow obstruction response.  During the obstruction, no flow 348 
exited from the ventricle to the VAD or aorta, and ventricular pressure increased 349 
as blood returned from the atrium until a pressure sufficient to “pop off” the 350 
cannula was reached and flow resumed.  This resulted in the alternating behavior 351 
between flow and complete flow obstruction (Fig. 5). 352 
 353 
4.1. Limitations and Future Work 354 
Since there is a lack of ventricular suction data specific to pediatric, single 355 
ventricle patients, equation 3 will require experimental validation in future studies.  356 
Despite this, results from suction model simulation testing (Table B1) provided 357 
confidence the model we developed improved over existing models at producing 358 
physiologically realistic results.  Additionally, the new model accounted for the 359 
possibility of complete flow obstruction, which prior models did not.  Even though 360 
equation 3 was developed from an amalgam of data applicable to various 361 
anatomies, it is strongly recommended that future computational studies employ 362 
a similar validation process as described in Appendix B. 363 
There remains a need for improvement to models describing ventricular 364 
suction resistance and the passive pressure-volume relationship at negative 365 
ventricular pressures.  The majority of existing work has focused on animal 366 
experiments, and it remains unknown how well these translate to humans.  It 367 
could be beneficial to explore in-vivo experiments and human data.  This would 368 
provide much needed advancements to critical components of simulations 369 
involving VADs.  While in-vitro experiments with postmortem hearts could be 370 
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orchestrated more easily, the lack of muscle tone and tissue would not be 371 
representative of a clinical situation.  Additionally, it would be beneficial for future 372 
computational studies to incorporate cardiovascular feedback mechanisms to 373 
simulate a patient’s long-term response to VAD treatment. 374 
Since ventricular contractility may be partially present during HF, 375 
synchronization of the VAD to the patient’s native heart can impact the efficacy of 376 
filling and ejection and consequently CO.  Simulations of co- and counter-377 
pulsation methods for pulsatile and pseudo-pulsatile continuous flow VADs show 378 
small physiological differences among syncing schemes (Neidlin et al., 2016; Shi 379 
et al., 2007), but incorporating our improved suction model may alter these 380 
previous findings. 381 
 382 
4.2. Conclusion 383 
In summary, our results predict VAD treatment outcomes for stage 1 384 
single ventricle patients by comparing performance between the pulsatile flow 385 
Berlin Heart EXCOR VAD and continuous flow HeartWare VAD.  We first 386 
developed an improved model for ventricular suction resistance using data from 387 
prior literature.  We then showed the continuous flow VAD produced greater CO 388 
by at least 0.99 L/min (p=0.001) for all patients.  The CO produced by the 50 mL 389 
Berlin Heart was as much as 1.4 L/min (37.3%) below expected due to 390 
incomplete filling caused by ventricular suction and shorter diastolic time at high 391 
HRs.  Optimizing VAD peak pressure and DFR settings from clinical 392 
recommendations increased CO by at most 0.07 L/min for each patient and failed 393 
to produce a statistically significant (p<0.05) improvement.  The Berlin Heart’s 394 
ability to produce CO ultimately remained filling limited.  Further work is needed 395 
to validate these findings over a broader population.  This study elucidates 396 
underlying mechanisms affecting outcomes of pulsatile and continuous flow VAD 397 
support in single ventricle patients and quantifies the impacts of ventricular 398 
suction, ventricular collapse, and incomplete filling on VAD supported 399 
physiologies. 400 
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Table and Figure Captions 571 
 572 
Fig. 1. Lumped-parameter network for a stage 1 single ventricle circulation on 573 
VAD support.  PSUBSCRIPT, pressure; QSUBSCRIPT, volumetric flowrate; LSUBSCRIPT, 574 
inductance; CSUBSCRIPT, capacitance; RSUBSCRIPT, linear resistance; KSUBSCRIPT, 575 
quadratic resistance; ESUBSCRIPT, elastance. 576 
 577 
Table 1. Cannula parameters for the Berlin Heart and HeartWare VAD 578 
simulations.  Values given are from manufacturer specifications when available.  579 
* Cannula dimensions simulated for HeartWare VAD were based on Revolution 580 
VAD case study (Lal et al., 2014) that used Berlin Heart cannulas.  A dash 581 
indicates the value was not provided or not applicable (i.e. head ID is same as 582 
body ID).  ID, inner diameter. 583 
 584 
Fig. 2. Expected (VAD stroke volume * VAD heart rate) versus simulated cardiac 585 
output of 10 and 25 mL Berlin Heart.  Data points represent cohort mean values. 586 
 587 
Fig. 3.  Resulting physiologies for the (a) 50 mL Berlin Heart and (b) HeartWare 588 
VAD.  Data points represent cohort mean values.  CO, cardiac output; RSUC, 589 
suction resistance; PSA, atrial pressure; PSV, ventricular pressure.   590 
 591 
Fig. 4.  Mean stroke volume (SV) and suction resistance (RSUC) versus VAD 592 
heart rate for the 25 and 50 mL Berlin Heart using clinical recommended VAD 593 
settings.  Data points represent cohort mean values. 594 
 595 
Table 2. Patient specific results for pulsatile and continuous flow VADs. CO are 596 
mean values for the last cardiac period and are in units of L/min.  NI, “no 597 
improvement” from clinical recommended VAD settings.  PDIA, peak filling 598 
pressure; PSYS, peak ejection pressure; PAO, aortic pressure DFR, diastolic filling 599 
ratio.    600 
 601 
Fig. 5.  Demonstration of phasic complete flow obstruction in one patient during 602 
continuous flow VAD support.  VAD flow (QVAD) dropped to zero when the 603 
cannula pressure (PCAN) decreased rapidly, which represented the start of a 604 
complete flow obstruction event.  During complete flow obstruction, ventricular 605 
volume (not shown) steadily increased with flow from the atrium to the ventricle 606 
(QAV).  Ventricular pressure (PSV) was slower to increase since ventricular 607 
volume started close to zero in the “flat” region of the passive pressure-volume 608 
curve. 609 
 610 
  611 
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Tables 612 
Table 1. 613 
 Inflow Cannula Outflow Cannula 
VAD Head ID (mm) 
Head 
Length 
(mm) 
Body 
ID 
(mm) 
Body 
Length 
(mm) 
Head ID 
(mm) 
Head 
Length 
(mm) 
Body 
ID 
(mm) 
Body 
Length 
(mm) 
10 mL Berlin Heart 6 18 6 232 6 - 6 250 
25 mL Berlin Heart 9 28 12 242 12 - 12 280 
50 mL Berlin Heart 9 28 12 242 12 - 12 280 
HeartWare VAD* 9 28 12 242 12 - 12 280 
 614 
Table 2.  615 
Patient A B C D E F 
Pre-HF CO 1.29 1.55 1.42 1.60 1.87 1.75 
Target VAD CO 1.80 1.56 2.04 1.68 2.04 1.62 
Pulsatile Flow 
Control CO 1.92 2.30 2.14 2.24 2.21 2.79 
Control Settings 25 mL 90 BPM 
50 mL 
60 BPM 
25 mL 
90 BPM 
50 mL 
45 BPM 
25 mL 
90 
BPM 
50 mL 
60 BPM 
Optimized CO 1.94 2.37 NI 2.26 NI 2.86 
Optimized 
Settings 
25 mL 
90 BPM 
80% 
DFR 
50 mL 
60 BPM 
PSYS = 200+PAO 
mmHg 
PDIA = -100 mmHg 
80% DFR 
NI  
50 mL 
60 BPM 
PSYS = 200+PAO 
mmHg 
PDIA = -100 mmHg 
80% DFR 
NI 
50 mL 
60 BPM 
PSYS = 200+PAO 
mmHg 
PDIA = -100 mmHg 
80% DFR 
Continuous Flow 
Control CO 3.11 3.36 3.35 3.50 3.31 4.08 
Rotor RPM 3400 3200 3000 3200 3400 3400 
  616 
 617 
  618 
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Supplemental Digital Content 1 
Appendix A 2 
For an LPN, there were two fundamental equations used to calculate the 3 
pressure and volumetric flowrate.  The general form of the differential equation 4 
for pressure was 5 
!"!" = !!                                                                       (A1) 6 
and for volumetric flowrate was 7 
!"!" = !!                                                                         (A2) 8 
Pressure and flowrate were related to resistance by 9 ∆𝑃 = 𝑄𝑅             (A3) 10 
Atrial and ventricular contraction was represented by an active-passive 11 
model.  With this model, the pressure can be calculated based on volume and 12 
the time in the cardiac period.  Two components were present:  a passive curve 13 
and an active curve for contraction.  The passive pressure-volume equation for 14 
positive pressures is 15 𝑃!"##$%&,! = 𝑐 𝑒! !!!! − 1              (A4) 16 
where c and d are patient specific parameters and Vo is the reference volume.  17 
The passive pressure-volume equation for negative pressures is 18 𝑃!"##$%&,! = 𝑆! ln !!!                     (A5) 19 
where Sn is a property describing tissue stiffness.  The active pressure-volume 20 
equation is 21 𝑃!"#$%& = !!!!!                (A6) 22 
  2 
where C is another patient specific parameter. 23 
An activation function describes the period of active contraction for the 24 
heart tissue.  When contraction occurs, AA(t) takes on a value between zero and 25 
one.  This is multiplied by Pactive and adds to the passive pressure.  In cases for 26 
which atrial pressure was negative, the activation function was set to zero.  This 27 
was to prevent adding a negative pressure predicted by equation A6 for atrial 28 
volumes less than V0.  The general activation function was 29 
𝐴𝐴 𝑡 = !! 1− cos 2𝜋 !!!!!!!!!                              𝑡 ≤ 𝑡!!! 1− cos 2𝜋 !!!!!!!!!           𝑡! + 𝑡! ≤ 𝑡 < 𝑡!0                                                                           𝑒𝑙𝑠𝑒        (A7) 30 
where t1, ts, td, and tc are the time at end of contraction, total time for systole, total 31 
time for diastole, and total time for one cardiac cycle respectively.  The equation 32 
for calculating the overall pressure is 33 
𝑃 𝑉, 𝑡 = 𝑃!"#$%&𝐴𝐴 𝑡 + 𝑃!"##$%&,!     𝑉 ≥ 0𝑃!"##$%&,!                                  𝑉 < 0                      (A8) 34 
The pressure drop through the systemic-to-pulmonary shunt was 35 
calculated with a model by Migliavacca et al. (Migliavacca et al., 2000) and is 36 ∆𝑃!" = 𝑅!"𝑄!" + 𝐾!"𝑄!"!                                      (A9) 37 
where RSH and KSH were patient specific parameters.  Similarly, flow through the 38 
heart valves was calculated as 39 
!!!"!" = 0                                 𝑃!" < 𝑃!"  𝑎𝑛𝑑 𝑄!" < 0!!"!!!"!!!"!!"!!!"                                           𝑒𝑙𝑠𝑒                     (A10) 40 
for the atrial-ventricular valve, where KAV is a patient specific parameter, and 41 
  3 
𝑄!" = 0                                                       𝑃!" < 𝑃!"!!"#! !!!!" !!"!!!" !!!"#!!!"        𝑃!" ≥ 𝑃!"                       (A11) 42 
for the aortic valve where RMYO, KAO are patient specific parameters. 43 
 For the pulsatile flow VAD model to represent a physical system, domain 44 
limits on volume were imposed.  The volume must remain between zero and the 45 
VAD size inclusive.  The volume of blood in the VAD was calculated at each 46 
iteration as the difference in the time rate of change of volume entering and 47 
leaving by 48 
!"!"!!" = !!!"#,!"!" − !!!"#,!"#!"                                                          (A12) 49 
The time derivative of volume is volumetric flowrate, so a more convenient form 50 
is 51 
!"!"#!" = 𝑄!"#,!" − 𝑄!"#,!"#                                                (A13) 52 
Since flow in the VAD cannulas may become turbulent due to high 53 
flowrates through a small ID cannula, we use the Darcy-Weisbach equation to 54 
model the pressure drop for both laminar and turbulent flow 55 ∆𝑃 = !!!!!!!!! 𝑄!                   (A14) 56 
where ΔP is the pressure drop, 𝑙 is the pipe length, fD is the dimensionless Darcy 57 
friction factor, ρ is the fluid density, and D is the pipe diameter.  Equation A14 58 
can be directly applied to the VAD cannulas since size dimensions and fluid 59 
properties are known.  The friction factor is a function of relative roughness, 60 
which is the quotient of absolute roughness to pipe diameter, and the Reynolds 61 
number.  The absolute roughness for Berlin Heart cannulas was assumed a 62 
  4 
conservative value representative of plastic tubing since no literature was 63 
available. 64 
For equation A14 to be valid, flow in the cannulas must be incompressible 65 
and fully developed.  Blood is typically considered incompressible at 66 
physiological pressures.  Fully developed fluid flow for turbulent Reynolds 67 
numbers can occur by 10 diameters of pipe length (Bergman et al., 2011), which 68 
occurs for the length majority for cannulas tested in this study. 69 
The friction factor, fD, for the VAD cannulas was calculated using two 70 
different equations depending on the flow regime.  For laminar flow (Re<2300), 71 
the equation was 72 𝑓! = !"!"           (A15) 73 
and for turbulent flow (Re>2300), the Haaland equation was used 74 
𝑓! = −1.8 log!" !!.!! !.!! + !.!!" !!       (A16) 75 
where ε is the absolute roughness of the cannula material.  The units of ε and D 76 
must match to form a dimensionless ratio. 77 
 A separate term for the dynamic pressure loss was also included for the 78 
inflow and outflow cannulas.  This is calculated by 79 𝑃 = 0.5𝑘!𝜌𝑉!           (A17) 80 
where kL is a minor loss factor dependent on geometry and is reported in 81 
introductory fluid mechanics textbooks.  In practice, it was found that this 82 
pressure loss was usually 5 mmHg or less.  For example, a kL of unity with a 83 
flowrate of 5 L/min and 12 mm ID cannula would result in a pressure loss of 84 
approximately 2.2 mmHg. 85 
  5 
 The pressure, PCOMP, of the pulsatile flow VAD was prescribed explicitly as 86 
a function of time by 87 
𝑃!"#$ = 𝑃!"! sin !∗!!!!"# ∗!!!" !.!                𝑠𝑦𝑠𝑡𝑜𝑙𝑒𝑃!"# sin !! !!!"# ∗!!"# ∗!!"#∗!!"#             𝑑𝑖𝑎𝑠𝑡𝑜𝑙𝑒                                 (A18) 88 
where tVAD is the time of one VAD period and DFR is the diastolic filling ratio (a 89 
number between zero and one).  An example waveform of equation 1 is shown in 90 
Fig. A1. 91 
 92 
Fig. A1. Equation A18 waveform for settings of PSYS = 150 mmHg, PDIA = -40 93 
mmHg, DFR = 0.60, and tVAD = 1 sec. 94 
 95 
We used experimental data from literature for the HeartWare VAD to 96 
reconstruct several trendlines in the general form of 97 ∆𝑃!"# = 𝐴𝑄!"#! + 𝐵𝑄!"# + 𝐶              (A19) 98 
where ΔPVAD is the pressure rise across the VAD, QVAD is the flowrate through 99 
the VAD, and A, B, and C are constants dependent on the RPM of the VAD 100 
(Moazami et al., 2013). 101 
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 102 
 103 
Fig. A2.  Reconstructed experimental data with quadratic best fit trendlines for 104 
the continuous flow HeartWare VAD 105 
  106 
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Appendix B 107 
The models from literature for ventricular resistance most suitable for use 108 
in our LPN were tested for validity in the pediatric patient circulation under study. 109 
The original concept of suction resistance is traceable to Schima et al. 110 
(Schima et al., 1990).  Results from that study were later expressed 111 
mathematically (Choi, 1998) as 112 
𝑅!"# = 0                                      𝑃!" > 𝑃!"−3.5𝑃!" + 3.5𝑃!"       𝑃!" ≤ 𝑃!"                                                   (B1) 113 
where RSUC was the suction resistance, PSA was the atrial pressure, and PTH was 114 
the threshold pressure for suction to occur.  Values of -1 and 0 mmHg have been 115 
used for PTH by later studies (Ochsner et al., 2013; Yu and Porter, 2006). 116 
 Two previous studies have presented models developed from least 117 
squares regression analysis of experimental data from animal experiments.  The 118 
development of these models was done retrospectively by finding the resistance 119 
that best recreated the experimental pressure and flowrate data based on the 120 
studied anatomy and physiology. 121 
The first of the two regression models was developed by Yu and Porter 122 
(Yu and Porter, 2006) and was 123 𝑅!"# = 𝑘 + 𝑎!𝑃!"#!!!!,!,!,! + 𝑏!𝑃!"!!!!! + 𝑐 !!" 𝑃!"                           (B2) 124 
where k is the constant resistance of the VAD cannula itself, PCAN is the pressure 125 
in the inflow cannula, PSV is the ventricular pressure, and a, b, and c are 126 
constants determined from the regression analysis.  Though not explicitly stated 127 
by the authors, RSUC was assumed zero for any negative values since a negative 128 
resistance has no physical meaning. 129 
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 The second of the regression models was developed by Lim et al. (Lim et 130 
al., 2010) and was 131 
!!!"#!" = !!!"#!!!"#,!!!!"#             (B3) 132 
where 𝜏!!"# was a time constant from the regression analysis.  𝑅!"#,! was 133 
modeled by 134 
𝑅!"#,! = 𝑘!! 𝑒!!! !!"!!!"         𝑉!" < 𝑉!"0                                       𝑉!" ≥ 𝑉!"                                         (B4) 135 
where ks1 and ks2 were constants determined from the regression analysis and 136 
VTH was the threshold volume for suction to occur.  We assumed a zero initial 137 
condition for RSUC.  The threshold volume originally used by Lim et al. was 138 
arbitrarily chosen as the volume at which the left ventricular pressure was equal 139 
to 5 mmHg.   For consistency with the other suction models tested, we instead 140 
chose the ventricular reference volume (for which PSV=0 mmHg) as the threshold 141 
volume. 142 
Simulations with these models were done for each patient using the 50 mL 143 
Berlin Heart at 75 BPM and the HeartWare VAD at 3400 RPM since these 144 
settings would have the greatest tendency for ventricular suction to occur (Table 145 
B1). 146 
Each suction model produced similar results for pulsatile flow, but results 147 
varied for continuous flow.  For the continuous flow case, the models of Schima 148 
and Lim predicted mean pressure drops of approximately 50 mmHg at ventricular 149 
pressures close to -1 mmHg.  This rapid suction response was unrealistic and 150 
these two models were not considered any further.  Conversely, the model by Yu 151 
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and Porter predicted a pressure drop of only 3.14 mmHg for a ventricular 152 
pressure of -7.67 mmHg.  This slow suction response was also unrealistic and 153 
this model was abandoned as well.  It was also expected that complete flow 154 
obstruction due to ventricular collapse could occur for the HeartWare VAD by 155 
3400 RPM.  This was another reason for dismissing these three models.  As a 156 
caveat, these models were derived at least in part from animal experiments.  157 
Therefore, they may be fairly accurate for circulations more similar to those of the 158 
original tests, but they did not appear well suited for pediatric human circulations. 159 
 We therefore propose a new model to describe the ventricular suction 160 
resistance, RSUC, at negative ventricular pressures.  To make the model valid for 161 
any BSA, an allometric scaling law between RSUC and anatomical parameters 162 
was desired.  We define a parameter called the skweeesh factor, Δ, which is 163 
expressed as 164 ∆= 𝐷!" + ℎ!" − 𝑙!               (B5) 165 
where DSV is the ventricular diameter, hSV is the ventricular wall thickness, and lh 166 
is the cannula head length.  If the skweeesh factor equals zero, then the cannula 167 
head length equals the ventricular diameter and thickness.  In such a situation, 168 
the suction resistance would be infinite since no flow can enter the cannula.  169 
Therefore, a general relation is established 170 𝑅!"# ∝ !∆             (B6) 171 
The scale factor of Δ with BSA was obtained by using equation B6 for several 172 
BSA values with corresponding ventricular diameter and thickness (Dawson, 173 
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2014) and cannula specifications from Berlin Heart.  Δ scaled with BSA0.3492, and 174 
so RSUC scaled with BSA-0.3492. 175 
 The experimental data during suction events from several studies (Lim et 176 
al., 2010; Salamonsen et al., 2015; Schima et al., 1990) was normalized by BSA 177 
to recast ventricular suction resistance independent of body size (Fig. B1).  A 178 
trendline equation (R2=0.72) was created by doing a best fit for a power model.  179 
This model was expressed as 180 
𝑅!"# = 0                                                                           𝑃!" > 𝑃!"0.2623 0.9787!!"# − 1 𝐵𝑆𝐴!!.!"#$          𝑃!" ≤ 𝑃!"                      (B7) 181 
 182 
 183 
Fig. B1.  Experimental suction resistance (RSUC) data obtained from prior studies 184 
and normalized by body surface area (BSA). 185 
 186 
Additionally, we developed a method to dynamically calculate the 187 
threshold pressure for VAD flow to resume.  This was derived from a force 188 
equilibrium between the negative force caused by cannula suction and the 189 
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positive force generated by ventricular pressure.  In other words, once a 190 
complete flow obstruction occurred, a sufficient positive pressure must build up in 191 
the ventricle to “pop off” the inflow cannula from the ventricular wall.  The force 192 
balance starts with 193 𝐹!" = 𝐹!"#               (B8) 194 
which can be expressed in terms of pressure by 195 𝑃!"𝐴!" = 𝑃!"#𝐴!"#                    (B9) 196 
and then ventricular surface area and cannula inner area by 197 𝑃!" 4𝜋𝑟!"! = 𝑃!"# !! 𝐷!"#!          (B10) 198 
The ventricular radius can be related to BSA by using clinical data (Troy et al., 199 
1972) to obtain 200 𝑟!" = 22.4035!!! 𝐵𝑆𝐴           (B11) 201 
Substituting this expression into the force balance simplifies to 202 𝑃!" = !!"# !!"#!!"#$!"#                (B12) 203 
where DCAN is in mm.  Values for the threshold pressure after a complete flow 204 
obstruction event typically range from 1-7 mmHg.  For reference, a cannula 205 
pressure of -100 mmHg, cannula diameter of 12 mm, and BSA of 0.30 m2 206 
produces a ventricular pressure threshold of 6.0 mmHg. 207 
Using the same suction model testing process, the new model was 208 
compared to existing models with respect to its ability to produce realistic 209 
physiology for the patients in this study.  The new model proposed in this study is 210 
named “Proposed” and produced realistic results for both test cases (Table B1).  211 
  12 
Although the mean value for RSUC is 43.6 mmHg.s/mL for PSV of 0.45 mmHg, this 212 
is because three patients experienced complete flow obstruction.  In these cases, 213 
RSUC was set arbitrarily to 100 mmHg.s/mL for numerical stability and VAD flow 214 
was set to zero until PSV reached PTH.  This new model requires further validation 215 
from experimentation in future work.  Obtaining clinical data in human circulations 216 
is difficult since ventricular suction is undesirable in the clinical setting, but this 217 
remains an important task to improve accuracy of computational simulation of 218 
VAD treatment. 219 
  220 
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Appendix C 221 
Table C1. Patient specific clinical measurements. Values are expressed as mean 222 
for last cardiac period.  QUB, upper body flow; QLB, lower body flow; QLPV, left 223 
pulmonary vein flow; QRPV, right pulmonary vein flow; CO, cardiac output; PSA, 224 
atrial pressure; PAO, aortic pressure; PPA, pulmonary artery pressure; QP/QS, ratio 225 
of pulmonary to systemic flow. 226 
Patient A B C D E F 
QUB (mL/s) 5.6 10.0 11.2 11.0 8.0 8.3 
QLB (mL/s) 5.7 5.0 5.7 4.0 3.0 6.0 
QLPV (mL/s) 4.5 4.0 2.7 6.5 9.0 8.1 
QRPV (mL/s) 5.2 8.0 4.8 5.5 11.0 8.5 
CO (mL/s) 21.0 27.0 24.4 27.0 31.0 29.8 
PSA (mmHg) 6.0 7.0 5.0 5.4 4.0 6.0 
PAO (mmHg) 52.0 53.0 43.0 53.0 72.0 51.0 
PPA  (mmHg) 12.0 15.5 13.0 12.7 13.5 11.0 
QP/QS 0.9 0.8 0.4 0.8 1.8 1.1 
 227 
 228 
229 
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Table C2. Absolute percent differences between clinical measurements and pre-230 
HF LPN results for each patient. QUB, upper body flow; QLB, lower body flow; 231 
QLPV, left pulmonary vein flow; QRPV, right pulmonary vein flow; CO, cardiac 232 
output; PSA, atrial pressure; PAO, aortic pressure; PPA, pulmonary artery pressure; 233 
QP/QS, ratio of pulmonary to systemic flow. 234 
Patient A B C D E F 
QUB 2.3 7.2 4.1 1.3 0.7 4.7 
QLB 1.2 1.4 2.6 2.0 1.0 1.5 
QLPV 4.9 19.8 1.5 2.0 4.8 1.4 
QRPV 8.8 17.3 1.7 4.9 0.2 12.5 
CO 1.9 4.4 2.9 1.5 0.5 2.0 
PSA 12.0 0.1 30.6 18.5 4.8 6.0 
PAO 0.3 2.2 1.9 0.2 0.3 0.2 
PPA 2.5 2.1 11.6 9.8 1.7 2.8 
QP/QS 3.5 3.8 2.3 5.0 8.3 7.3 
 235 
 236 
237 
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Appendix D 238 
Table D1. Patient specific data for zero ventricular contractility and no VAD 239 
support.  Values are expressed as mean for last cardiac period.  CO, cardiac 240 
output; VSA, atrial volume; VSV, ventricular volume; PSA, atrial pressure; PSV, 241 
ventricular pressure; PAO, aortic pressure; PPA, pulmonary artery pressure; 242 
QP/QS, ratio of pulmonary to systemic flow. 243 
Patient A B C D E F 
CO (L/min) 0.20 0.12 0.04 0.21 0.45 0.16 
VSA (mL) 10.11 20.17 11.13 22.84 37.61 21.99 
VSV (mL) 37.29 41.01 22.82 48.71 49.59 34.15 
PSA (mmHg) 9.77 13.55 15.52 12.31 6.71 10.27 
PSV (mmHg) 13.83 15.40 16.29 15.95 15.45 12.08 
PAO (mmHg) 13.68 15.30 16.26 15.78 15.14 11.95 
PPA (mmHg) 11.26 14.54 15.96 13.8 9.66 10.93 
QP/QS 2.53 2.63 1.27 2.12 4.39 3.91 
 244 
245 
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Table D2. Optimal patient specific outcomes for pulsatile flow (higher of either 246 
clinical or modified settings) and continuous flow VADs.  Values are expressed 247 
as mean for last cardiac period.  Patients with VMAX equal to 25 mL had optimal 248 
results with 25 mL size Berlin Heart.  The settings used to obtain these data are 249 
reported in Table E1.  CO, cardiac output; VSA, atrial volume; VSV, ventricular 250 
volume; PSA, atrial pressure; PSV, ventricular pressure; PAO, aortic pressure; PPA, 251 
pulmonary artery pressure; QP/QS, ratio of pulmonary to systemic flow; RSUC, 252 
suction resistance; VMIN, minimum VAD volume; VMAX, maximum VAD volume. 253 
Pulsatile Flow 
Patient A B C D E F 
CO (L/min) 1.94 2.37 2.14 2.26 2.21 2.86 
VSA (mL) 4.05 9.66 4.33 10.72 25.28 12.59 
VSV (mL) 4.29 4.00 6.45 3.95 8.84 7.02 
PSA (mmHg) 1.36 1.74 1.06 1.99 2.61 2.32 
PSV (mmHg) 0.09 0.10 0.00 0.06 0.52 0.02 
PAO (mmHg) 80.83 82.03 60.67 76.74 89.39 87.25 
PPA (mmHg) 9.68 12.56 11.40 11.59 13.34 9.08 
QP/QS 0.73 0.61 0.37 0.68 1.61 0.80 
RSUC (mmHg.s/mL) 0.10 0.16 0.06 0.16 0.05 0.16 
VMIN (mL) 0.00 0.00 0.00 0.00 0.00 0.00 
VMAX (mL) 24.76 39.92 25.00 43.70 25.00 48.14 
Continuous Flow 
Patient A B C D E F 
CO (L/min) 3.11 3.36 3.35 3.50 3.31 4.08 
VSA (mL) 0.85 1.10 0.81 1.15 15.14 6.17 
VSV (mL) 1.55 1.81 1.47 1.90 3.05 4.10 
PSA (mmHg) -4.68 -1.34 -6.06 -1.48 0.20 0.69 
PSV (mmHg) -6.86 -4.38 -8.25 -4.50 -1.93 -3.58 
PAO (mmHg) 133.80 118.60 92.50 117.40 143.01 128.45 
PPA (mmHg) 6.90 12.52 8.06 11.45 15.48 9.51 
QP/QS 0.57 0.53 0.31 0.53 1.33 0.69 
RSUC (mmHg.s/mL) 0.14 0.10 0.20 0.11 0.03 0.12 
 254 
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Appendix E 255 
 We investigated several pulsatile flow VAD settings different from current 256 
clinical implementation with the goal of optimizing CO.  Investigations were done 257 
with the 50 mL Berlin Heart only since mean CO was as much as 37.3% below 258 
expected (compared to 0% and 9.7% for the 10 and 25 mL sizes).  Since 259 
incomplete filling was the limiting factor to CO, adjustments were made to peak 260 
VAD pressures and DFR, which are also adjustable in clinical practice.  Although 261 
flow resistance could be reduced with a larger ID cannula, we chose not model 262 
such cases since surgical limitations of the pediatric ventricle would not 263 
accommodate cannula ID larger than the 12 mm already modeled.  These 264 
modifications and combinations of VAD settings were simulated for all patients.  265 
Results at 60 BPM produced the highest cardiac index (CI) in all cases while 266 
remaining within the limits of the air compressor. 267 
None of the modifications to pulsatile flow VAD settings (Table E1) 268 
produced statistically significant differences from clinical implementation 269 
simulations (case 1) with respect to CI, and the best result (case 6) produced 270 
only a 2.4% increase in CI.  When combining the PDIA = -100 mmHg and DFR = 271 
65% settings (case 4), filling improved enough to result in nonzero VMIN, which 272 
signaled incomplete ejection, thus we further increased PSYS to improve ejection 273 
(case 5).  Next, we increased DFR to 80% to further increase time for filling, 274 
which produced another 1.0% increase to CI (case 6).  Statistically significant 275 
increases in RSUC did occur in most cases since improved filling increased the 276 
VAD’s demand for blood from the ventricle. 277 
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 278 
Table E1. Modifications to VAD settings for 50 mL Berlin Heart to improve filling.  279 
Values are expressed as cohort mean (standard deviation).  * denotes statistical 280 
significance for p<0.05.  CI, cardiac index; RSUC, suction resistance; PDIA, peak 281 
filling pressure; PSYS, peak ejection pressure; PAO, aortic pressure DFR, diastolic 282 
filling ratio. 283 
Case VAD Setting Change Rationale CI                 (L/min/m2) 
RSUC                        
(mmHg.s/mL) 
CI           
p-Value 
RSUC 
p-Value 
1 Control  7.63 (1.72) 0.06 (0.01)   
2 PDIA = -100 mmHg 
Larger pressure 
gradient for filling 7.63 (1.72) 0.12 (0.01) 1.0000 1.940.10
-5* 
3 DFR = 65% Increased time for filling 7.64 (1.74) 0.07 (0.01) 0.9854 0.1902 
4 PDIA = -100 mmHg DFR = 65% Combine cases 2 and 3 7.65 (1.74) 0.13 (0.01) 0.9707 3.706.10
-6* 
5 
PSYS = PAO+200 mmHg 
PDIA = -100 mmHg 
DFR = 65% 
Incomplete ejection 
occurred in case 4, thus 
increased peak ejection 
pressure 
7.73 (1.77) 0.13 (0.01) 0.8777 8.992.10-7* 
6 
PSYS = PAO+200 mmHg 
PDIA = -100 mmHg 
DFR = 80% 
Further increased time 
for filling 7.81 (1.78) 0.16 (0.01) 0.7729 6.018.10
-9* 
 284 
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